Dendritic Cell Vaccine for Prostate Cancer from Germany
Autologous dendritic cells loaded with tumor-associated antigens (e.g., Provenge/sipuleucel-T), matured ex vivo for personalized cancer vaccination. HTS 3002.51.00.00 applies to these as cell therapy products—modified cell cultures for active immunotherapy. They prime T-cell responses against prostate cancer cells.
Duty Rate — Germany → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Include antigen pulsing validation and DC maturation markers in shipment docs
• Patient-specific labeling required—match lot to clinical records